Director, President and CEO of Assertio Therapeutics Inc (30-Year Financial, Insider Trades) Arthur J Higgins (insider trades) bought 50,000 shares of ASRT on 08/12/2019 at an average price of $1.54 a share. The total cost of this purchase was $77,000.
Depomed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. Assertio Therapeutics Inc has a market cap of $97.900 million; its shares were traded at around $1.52 with and P/S ratio of 0.44. Assertio Therapeutics Inc had annual average EBITDA growth of 33.80% over the past five years. GuruFocus has detected 4 severe warning signs with Assertio Therapeutics Inc. .
CEO Recent Trades:
- Director, President and CEO Arthur J Higgins bought 50,000 shares of ASRT stock on 08/12/2019 at the average price of $1.54. The price of the stock has decreased by 1.3% since.
CFO Recent Trades:
- SVP and CFO Daniel A. Peisert bought 19,000 shares of ASRT stock on 08/12/2019 at the average price of $1.57. The price of the stock has decreased by 3.18% since.
For the complete insider trading history of ASRT, click here
.
